Association of Vaginal Microbiota Composition with Human Papillomavirus Persistence in Cervical Dysplasia and Cervical Cancer: a Systematic Review and Meta-Analysis

Elyanora A. Kydyrbayeva 1 * , Yerbolat M. Iztleuov 2, Indira A. Azamatova 1, Gulmira M. Iztleuova 3, Yerlan Bakhytovich Sultangereyev 4, Nurgul Abdullaevna Abenova 5
More Detail
1 Department of Obstetrics and Gynecology, NJSC “Marat Ospanov West Kazakhstan Medical University”, Aktobe, Kazakhstan
2 Department of Radiology, Department of Radiology, NJSC “Marat Ospanov West Kazakhstan Medical University”, Aktobe, Kazakhstan
3 Department of Phthisiology and Dermatovenereology, NJSC “Marat Ospanov West Kazakhstan Medical University”, Aktobe, Kazakhstan
4 Department of Surgical Diseases No. 2, NJSC “Marat Ospanov West Kazakhstan Medical University”, Aktobe, Kazakhstan
5 Vice-Rector, NJSC “Marat Ospanov West Kazakhstan Medical University”, Aktobe, Kazakhstan
* Corresponding Author
J CLIN MED KAZ, Volume 23, Issue 3, pp. 92-102. https://doi.org/10.23950/jcmk/18531
OPEN ACCESS 648 Views 175 Downloads
Download Full Text (PDF)

ABSTRACT

Introduction: Persistent high-risk human papillomavirus (hrHPV) infection is the main step in cervical carcinogenesis. The vaginal microbiota may modulate this risk, but the evidence is heterogeneous. This is because previous reviews have not provided a quantitative synthesis that specifically examines the persistence of HPV in the full progression of disease from dysplasia to invasive cancer. This specific gap reduces the transition of microbiota research into the stratification of clinical risks. The aim of the research is to systematically review and meta-analyze the association between the composition of the vaginal microbiota and hrHPV persistence in women with cervical dysplasia and cancer.
Methods: The researcher searched PubMed, Embase, Cochrane Library, and Web of Science (Jan 2015-Feb 2026) for observational studies. Pooled odds ratios (ORs) were calculated using a random-effects model. Study quality was assessed using the Newcastle-Ottawa Scale.
Results: Twenty-four studies were included. A non-Lactobacillus-dominant microbiota was related with 2.5 times higher odds of hrHPV persistence (pooled OR 2.51, 95% CI 1.95-3.23, I²=68%, 18 studies). The relationship was stronger in women with invasive cervical cancer (OR 3.40) than in those with dysplasia only (OR 2.15).
Conclusion: Vaginal dysbiosis is significantly related to hrHPV persistence, with a significant effect in cervical cancer. The vaginal microbiome represents a potential biomarker for the stratification of risk and a target for therapeutic intervention, though clinical validation is needed before moving into clinical practice.
Keywords: vaginal microbiome, papillomavirus infections, uterine cervical dysplasia, uterine cervical neoplasms, disease progression.

CITATION

Kydyrbayeva EA, Iztleuov YM, Azamatova IA, Iztleuova GM, Sultangereyev YB, Abenova NA. Association of Vaginal Microbiota Composition with Human Papillomavirus Persistence in Cervical Dysplasia and Cervical Cancer: a Systematic Review and Meta-Analysis. J CLIN MED KAZ. 2026;23(3):92-102. https://doi.org/10.23950/jcmk/18531

REFERENCES

  • Zhang X, Zeng Q, Cai W, Ruan W. Trends of cervical cancer at global, regional, and national level: data from the Global Burden of Disease study 2019. BMC Public Health. 2021; 21(1): 894. https://doi.org/10.1186/s12889-021-10907-5
  • World Health Organization. Cervical cancer. 2025 Dec 25 [cited 2026 Jan 27]. Available from: https://www.who.int/news-room/fact-sheets/detail/cervical-cancer
  • Feng T, Yang Y. Risk factors contributing to the persistent infection of high-risk human papillomavirus (HPV). Eur J Gynaecol Oncol. 2025; 46(5). https://doi.org/10.22514/ejgo.2025.060
  • Wei F, Georges D, Man I, Baussano I, Clifford GM. Causal attribution of human papillomavirus genotypes to invasive cervical cancer worldwide: a systematic analysis of the global literature. Lancet. 2024; 404(10451): 435-444. https://doi.org/10.1016/S0140-6736(24)01097-3
  • Okunade KS. Human papillomavirus and cervical cancer. J Obstet Gynaecol. 2020; 40(5): 602-608. https://doi.org/10.1080/01443615.2019.1634030
  • Zhang Y, Ni Z, Wei T, Liu Q. Persistent HPV infection after conization of cervical intraepithelial neoplasia: A systematic review and meta-analysis. BMC Womens Health. 2023; 23(1): 216. https://doi.org/10.1186/s12905-023-02360-w
  • Zhao M, Zhou D, Zhang M, Kang P, Cui M, Zhu L, Luo L. Characteristic of persistent human papillomavirus infection in women worldwide: a meta-analysis. PeerJ. 2023; 11:e16247. https://doi.org/10.7717/peerj.16247
  • Chen J, Zhang M, Gong Y, Gu Z, Zhou H, Gu Y, Shen F, Zhou G, Ding J. The role of the vaginal microbiome in immune modulation in cervical cancer. Clin Med Insights Oncol. 2025; 19:11795549251380470. https://doi.org/10.1177/11795549251380470
  • Cui M, Wu Y, Liu Z, Liu Y, Fan L. Advances in the interrelated nature of vaginal microecology, HPV infection, and cervical lesions. Front Cell Infect Microbiol. 2025; 15:1608195. https://doi.org/10.3389/fcimb.2025.1608195
  • Li L, Ding L, Gao T, Lyu Y, Wang M, Song L, Li X, Gao W, Han Y, Jia H, Wang J. Association between vaginal micro-environment disorder and cervical intraepithelial neoplasia. J Cancer. 2020; 11(2): 284-292. https://doi.org/10.7150/jca.35022
  • Chopra C, Bhushan I, Mehta M, Koushal T, Gupta A, Sharma S, Kumar M, Khodor SA, Sharma S. Vaginal microbiome: considerations for reproductive health. Future Microbiol. 2022;17(18):1501-1513. https://doi.org/10.2217/fmb-2022-0112
  • Di Pierro F. Lactobacillus crispatus M247: A possible tool to counteract CST IV. Int J Nutraceuticals Funct Foods Novel Foods. 2018. https://doi.org/10.17470/NF-018-0001-4
  • Odogwu NM, Onebunne CA, Chen J, Ayeni FA, Walther-Antonio MR, Olayemi OO, Chia N, Omigbodun AO. Lactobacillus crispatus thrives in pregnancy hormonal milieu. Sci Rep. 2021; 11(1): 18152. https://doi.org/10.1038/s41598-021-96339-y
  • Petrova MI, Lievens E, Malik S, Imholz N, Lebeer S. Lactobacillus species as biomarkers and agents that can promote vaginal health. Front Physiol. 2015; 6:81. https://doi.org/10.3389/fphys.2015.00081
  • Laesche M, Urban H, Gallwas J, Gruendker C. HPV and other microbiota: effects on cervical cancer development. Cells. 2021;10(3):714. https://doi.org/10.3390/cells10030714
  • Gardella B, Pasquali MF, La Verde M, Cianci S, Torella M, Dominoni M. Interplay between vaginal microbiota and HPV infection. Int J Mol Sci. 2022; 23(13):7174. https://doi.org/10.3390/ijms23137174
  • Byrne EH, Doherty KE, Bowman BA, Yamamoto HS, Soumillon M, Padavattan N, Ismail N, Moodley A, Sabatini ME, Ghebremichael MS, Nusbaum C. Cervicovaginal bacteria modulate inflammatory responses. Immunity. 2015; 42(5): 965-976. https://doi.org/10.1016/j.immuni.2015.04.019
  • Kyrgiou M, Mitra A, Moscicki AB. Does the vaginal microbiota play a role in cervical cancer?. Transl Res. 2017; 179: 168-182. https://doi.org/10.1016/j.trsl.2016.07.004
  • Łaniewski P, Ilhan ZE, Herbst-Kralovetz MM. The microbiome and gynaecological cancer. Nat Rev Urol. 2020; 17(4): 232-250. https://doi.org/10.1038/s41585-020-0286-z
  • Borgogna JL, Shardell MD, Yeoman CJ, Ghanem KG, Kadriu H, Ulanov AV, Gaydos CA, Hardick J, Robinson CK, Bavoil PM, Ravel J. The association of Chlamydia trachomatis and Mycoplasma genitalium infection with the vaginal metabolome. Sci Rep. 2020; 10(1): 3420. https://doi.org/10.1038/s41598-020-60179-z
  • Norenhag J, Du J, Olovsson M, Verstraelen H, Engstrand L, Brusselaers N. The vaginal microbiota, human papillomavirus and cervical dysplasia: a systematic review and network meta-analysis. BJOG. 2020;127(2):171-180. https://doi.org/10.1111/1471-0528.15854
  • Mei L, Wang T, Chen Y, Wei D, Zhang Y, Cui T, Meng J, Zhang X, Liu Y, Ding L, Niu X. Dysbiosis of vaginal microbiota associated with persistent high-risk human papillomavirus infection. J Transl Med. 2022; 20(1): 12. https://doi.org/10.1186/s12967-021-03201-w
  • Zeng M, Li X, Jiao X, Cai X, Yao F, Xu S, Huang X, Zhang Q, Chen J. Roles of vaginal flora in human papillomavirus infection, virus persistence and clearance. Front Cell Infect Microbiol. 2023; 12:1036869. https://doi.org/10.3389/fcimb.2022.1036869
  • van de Wijgert JH, Verwijs MC. Lactobacilli-containing vaginal probiotics to cure or prevent bacterial or fungal vaginal dysbiosis: a systematic review. BJOG. 2020; 127(2): 287-299. https://doi.org/10.1111/1471-0528.15870
  • Cuschieri K, Ronco G, Lorincz A, Smith L, Ogilvie G, Mirabello L, Carozzi F, Cubie H, Wentzensen N, Snijders P, Arbyn M. Eurogin roadmap 2017: triage strategies for the management of HPV-positive women in cervical screening programs. Int J Cancer. 2018; 143(4): 735-745. https://doi.org/10.1002/ijc.31261
  • Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD, Shamseer L, Tetzlaff JM, Akl EA, Brennan SE, Chou R. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ. 2021; 372:n71. https://doi.org/10.1136/bmj.n71
  • British Educational Research Association (BERA). Ethical guidelines for educational research. 4th ed. London: British Educational Research Association; 2018. Available from: https://www.bera.ac.uk/publication/ethical-guidelines-for-educational-research-2018
  • British Psychological Society (BPS). BPS code of human research ethics. Leicester: British Psychological Society; 2021. Available from: https://www.bps.org.uk/news-and-policy/bps-code-human-research-ethics
  • O’Callaghan JL, Willner D, Buttini M, Huygens F, Pelzer ES. Limitations of 16S rRNA gene sequencing to characterize Lactobacillus species in the upper genital tract. Front Cell Dev Biol. 2021; 9:641921. https://doi.org/10.3389/fcell.2021.641921
  • Hutton B, Salanti G, Caldwell DM, Chaimani A, Schmid CH, Cameron C, Ioannidis JP, Straus S, Thorlund K, Jansen JP, Mulrow C. The PRISMA extension statement for reporting of systematic reviews incorporating network meta-analyses of health care interventions. Ann Intern Med. 2015; 162(11): 777-784. https://doi.org/10.7326/M14-2385
  • Gualdi-Russo E, Zaccagni L. The Newcastle–Ottawa Scale for assessing the quality of studies in systematic reviews. Publications. 2026; 14(1): 4.https://doi.org/10.3390/publications14010004
  • Quigley JM, Thompson JC, Halfpenny NJ, Scott DA. Critical appraisal of nonrandomized studies—a review of recommended and commonly used tools. J Eval Clin Pract. 2019; 25(1): 44-52. https://doi.org/10.1111/jep.12889
  • DerSimonian R, Laird N. Meta-analysis in clinical trials revisited. Contemp Clin Trials. 2015; 45: 139-145. https://doi.org/10.1016/j.cct.2015.09.002
  • Langan D, Higgins JP, Jackson D, Bowden J, Veroniki AA, Kontopantelis E, Viechtbauer W, Simmonds M. A comparison of heterogeneity variance estimators in simulated random-effects meta-analyses. Res Synth Methods. 2019; 10(1): 83-98. https://doi.org/10.1002/jrsm.1316
  • Jin ZC, Zhou XH, He J. Statistical methods for dealing with publication bias in meta-analysis. Stat Med. 2015; 34(2): 343-360. https://doi.org/10.1002/sim.6342
  • Lin L, Chu H, Murad MH, Hong C, Qu Z, Cole SR, Chen Y. Empirical comparison of publication bias tests in meta-analysis. Journal of general internal medicine. 2018; 33(8):1260-7. https://doi.org/10.1007/s11606-018-4425-7.
  • Furuya-Kanamori L, Barendregt JJ, Doi SA. A new improved graphical and quantitative method for detecting bias in meta-analysis. JBI Evidence Implementation. 2018; 16(4):195-203. https://doi.org/10.1097/xeb.0000000000000141.
  • Tugwell P, Tovey D. PRISMA 2020. Journal of Clinical Epidemiology. 2021; 134:A5-6. https://doi.org/10.1016/j.jclinepi.2021.04.008.
  • Selçuk AA. A guide for systematic reviews: PRISMA. Turkish archives of otorhinolaryngology. 2019; 57(1):57. https://doi.org/10.5152/tao.2019.4058.
  • Alhamlan FS, Albadawi IA, Al-Qahtani AA, Awartani KA, Obeid DA, Tulbah AM. Cervicovaginal and gastrointestinal microbiomes in gynecological cancers and their roles in therapeutic intervention. Frontiers in Microbiology. 2024; 15:1489942. https://doi.org/10.3389/fmicb.2024.1489942.
  • Logel MA. The Cervicovaginal Microbiome in Human Papillomavirus-Associated Cervical Carcinogenesis: Potential Value for Clinical Practice. McGill University (Canada); 2024. https://www.proquest.com/openview/3d7bfa2b9cce978cf82be5a48390b14d/1?pq-origsite=gscholar&cbl=18750&diss=y.
  • Bertoli HK, Thomsen LT, Iftner T, Dehlendorff C, Kjær SK. Risk of vulvar, vaginal and anal high-grade intraepithelial neoplasia and cancer according to cervical human papillomavirus (HPV) status: A population-based prospective cohort study. Gynecologic oncology. 2020; 157(2):456-62. https://doi.org/10.1016/j.ygyno.2020.01.030.
  • Kero K, Rautava J, Syrjänen K, Grenman S, Syrjänen S. Association of asymptomatic bacterial vaginosis with persistence of female genital human papillomavirus infection. European Journal of Clinical Microbiology & Infectious Diseases. 2017; 36(11):2215-9. https://doi.org/10.1007/s10096-017-3048-y.
  • Qulu W, Mtshali A, Osman F, Ndlela N, Ntuli L, Mzobe G, Naicker N, Garrett N, Rompalo A, Mindel A, Ngcapu S. High-risk human papillomavirus prevalence among South African women diagnosed with other STIs and BV. PLoS One. 2023; 18(11):e0294698. https://doi.org/10.1371/journal.pone.0294698.
  • Giannini A, Di Donato V, Sopracordevole F, Ciavattini A, Ghelardi A, Vizza E, D’Oria O, Simoncini T, Plotti F, Casarin J, Golia D’Augè T. Outcomes of high-grade cervical dysplasia with positive margins and HPV persistence after cervical conization. Vaccines. 2023; 11(3):698. https://doi.org/10.3390/vaccines11030698.
  • Musa J, Maiga M, Green SJ, Magaji FA, Maryam AJ, Okolo M, Nyam CJ, Cosmas NT, Silas OA, Imade GE, Zheng Y. Vaginal microbiome community state types and high-risk human papillomaviruses in cervical precancer and cancer in North-central Nigeria. BMC cancer. 2023; 23(1):683. https://doi.org/10.1186/s12885-023-11187-5.
  • Cheng X, Luo H, Ma J, Wang Y, Su J. Correlation between Indicators of Vaginal Microbiota and Human Papillomavirus Infection: A Retrospective Study. Clinical and Experimental Obstetrics & Gynecology. 2024; 51(4):94. https://doi.org/10.31083/j.ceog5104094.
  • Di Paola M, Sani C, Clemente AM, Iossa A, Perissi E, Castronovo G, Tanturli M, Rivero D, Cozzolino F, Cavalieri D, Carozzi F. Characterization of cervico-vaginal microbiota in women developing persistent high-risk Human Papillomavirus infection. Scientific reports. 2017; 7(1):10200. https://doi.org/10.1038/s41598-017-09842-6.
  • Murall CL, Rahmoun M, Selinger C, Baldellou M, Bernat C, Bonneau M, Boué V, Buisson M, Christophe G, D’auria G, De Taroni F. Natural history, dynamics, and ecology of human papillomaviruses in genital infections of young women: protocol of the PAPCLEAR cohort study. BMJ open. 2019; 9(6):e025129. https://doi.org/10.1136/bmjopen-2018-025129.
  • Suehiro TT, Malaguti N, Damke E, Uchimura NS, Gimenes F, Souza RP, da Silva VR, Consolaro ME. Association of human papillomavirus and bacterial vaginosis with increased risk of high-grade squamous intraepithelial cervical lesions. International Journal of Gynecological Cancer. 2019; 29(2):242-9. https://doi.org/10.1136/ijgc-2018-000076.
  • Kęczkowska E, Wrotyńska-Barczyńska J, Bałabas A, Piątkowska M, Dąbrowska M, Czarnowski P, Hennig EE, Brązert M, Olcha P, Ciebiera M, Zeber-Lubecka N. Harnessing the Power of Microbiota: How Do Key Lactobacillus Species Aid in Clearing High-Risk Human Papilloma Virus Infection and Promoting the Regression of Cervical Dysplasia? Biology. 2025; 14(8):1081. https://doi.org/10.3390/biology14081081.
  • Arokiyaraj S, Seo SS, Kwon M, Lee JK, Kim MK. Association of cervical microbial community with persistence, clearance and negativity of Human Papillomavirus in Korean women: a longitudinal study. Scientific reports. 2018; 8(1):15479. https://doi.org/10.1038/s41598-018-33750-y.
  • Tsementzi D, Meador R, Eng T, Shelton J, Scott I, Konstantinidis KT, Modesitt S, Bruner DW. Associations among HPV persistence, the vaginal microbiome, and cervical cancer recurrence. Journal of Translational Medicine. 2025; 23(1):858. https://doi.org/10.1186/s12967-025-06811-w.
  • Rizzo AE, Gordon JC, Berard AR, Burgener AD, Avril S. The female reproductive tract microbiome—implications for gynecologic cancers and personalized medicine. Journal of Personalized Medicine. 2021; 11(6):546. https://doi.org/10.3390/jpm11060546.
  • Cheng L, Norenhag J, Hu YO, Brusselaers N, Fransson E, Ährlund-Richter A, Guðnadóttir U, Angelidou P, Zha Y, Hamsten M, Schuppe-Koistinen I. Vaginal microbiota and human papillomavirus infection among young Swedish women. NPJ Biofilms and Microbiomes. 2020; 6(1):39. https://doi.org/10.1038/s41522-020-00146-8.
  • Pedrosa TF, Magalhães Filho SD, Peres AL. Profile of women with cervical changes from a city in the Northeast Brazil. Jornal Brasileiro de Patologia e Medicina Laboratorial. 2019; 55(1):32-43. https://doi.org/10.5935/1676-2444.20190004.
  • Mountain KE, MacIntyre DA, Lee YS, Tajadura-Ortega V, Dell A, Haslam SM, Wu G, Grassi P, Feizi T, Liu Y, Chai W. ABO blood group antigens influence host–microbe interactions and risk of early spontaneous preterm birth. NPJ Biofilms and Microbiomes. 2025; 11(1):170. https://doi.org/10.1038/s41522-025-00783-x.
  • Curty G, de Carvalho PS, Soares MA. The role of the cervicovaginal microbiome on the genesis and as a biomarker of premalignant cervical intraepithelial neoplasia and invasive cervical cancer. International journal of molecular sciences. 2019; 21(1):222. https://doi.org/10.3390/ijms21010222.
  • Marques MP, Pinto AC, Soares LC, Macedo JM, Dos Santos DF, de Oliveira MA. Protease inhibitor effects on prevalence of bacterial vaginosis and human papillomavirus‐related lesions. Journal of Obstetrics and Gynaecology Research. 2020; 46(6):899-906. https://doi.org/10.1111/jog.14245.
  • Damgaard RK, Jenkins D, Stoler MH, de Koning M, van de Sandt M, Lycke KD, Kahlert J, Gravitt PE, Quint WG, Steiniche T, Petersen LK. Human papillomavirus genotypes and risk of persistence and progression in women undergoing active surveillance for cervical intraepithelial neoplasia grade 2. American Journal of Obstetrics and Gynecology. 2024; 230(6):655-e1. https://doi.org/10.1016/j.ajog.2024.01.029.
  • Loonen AJ, Verhagen F, Luijten-de Vrije I, Lentjes-Beer M, Huijsmans CJ, van den Brule AJ. Vaginal dysbiosis seems associated with hrHPV infection in women attending the Dutch Cervical Cancer Screening Program. Frontiers in Cellular and Infection Microbiology. 2024; 14:1330844. https://doi.org/10.3389/fcimb.2024.1330844.
  • Lin W, Zhang Q, Chen Y, Dong B, Xue H, Lei H, Lu Y, Wei X, Sun P. Changes of the vaginal microbiota in HPV infection and cervical intraepithelial neoplasia: a cross-sectional analysis. Scientific reports. 2022; 12(1):2812. https://doi.org/10.1038/s41598-022-06731-5.
  • Bautista J, Altamirano-Colina A, López-Cortés A. The vaginal microbiome in HPV persistence and cervical cancer progression. Front Cell Infect Microbiol. 2025; 15:1634251. https://doi:10.3389/fcimb.2025.1634251